KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock Fundamental Analysis
NASDAQ:KZIA - Nasdaq - US48669G2049 - ADR - Currency: USD
KZIA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. KZIA may be in some trouble as it scores bad on both profitability and health. KZIA shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
KZIA had negative earnings in the past year.
In the past year KZIA has reported a negative cash flow from operations.
KZIA had negative earnings in each of the past 5 years.
In the past 5 years KZIA always reported negative operating cash flow.
1.2 Ratios
KZIA has a Return On Assets of -124.06%. This is amonst the worse of the industry: KZIA underperforms 80.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -124.06% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-88.87%
ROA(5y)-67.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for KZIA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, KZIA has more shares outstanding
The number of shares outstanding for KZIA has been reduced compared to 5 years ago.
Compared to 1 year ago, KZIA has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -12.15, we must say that KZIA is in the distress zone and has some risk of bankruptcy.
KZIA's Altman-Z score of -12.15 is on the low side compared to the rest of the industry. KZIA is outperformed by 79.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.15 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
KZIA has a Current Ratio of 0.24. This is a bad value and indicates that KZIA is not financially healthy enough and could expect problems in meeting its short term obligations.
KZIA has a worse Current ratio (0.24) than 96.81% of its industry peers.
KZIA has a Quick Ratio of 0.24. This is a bad value and indicates that KZIA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of KZIA (0.24) is worse than 96.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.24 | ||
| Quick Ratio | 0.24 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 92.01% over the past year.
The Revenue has grown by 10183.69% in the past year. This is a very strong growth!
The Revenue has been growing by 87.68% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)92.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.77%
Revenue 1Y (TTM)10183.69%
Revenue growth 3Y-46.59%
Revenue growth 5Y87.68%
Sales Q2Q%N/A
3.2 Future
KZIA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 154.72% yearly.
The Revenue is expected to grow by 31.98% on average over the next years. This is a very strong growth
EPS Next Y27.27%
EPS Next 2Y-583.06%
EPS Next 3Y-25.99%
EPS Next 5Y154.72%
Revenue Next Year0%
Revenue Next 2Y-64.17%
Revenue Next 3Y4.7%
Revenue Next 5Y31.98%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KZIA. In the last year negative earnings were reported.
KZIA is valuated quite expensively with a Price/Forward Earnings ratio of 157.74.
Based on the Price/Forward Earnings ratio, KZIA is valued cheaper than 90.80% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 95.03. KZIA is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 157.74 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates KZIA does not grow enough to justify the current Price/Earnings ratio.
A cheap valuation may be justified as KZIA's earnings are expected to decrease with -25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-583.06%
EPS Next 3Y-25.99%
5. Dividend
5.1 Amount
KZIA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KAZIA THERAPEUTICS-SPON ADR
NASDAQ:KZIA (2/5/2025, 8:10:49 PM)
After market: 1.4191 +0.02 (+1.36%)1.4
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.36%
Inst Owner Change-4.49%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.05M
Analysts82.86
Price Target19.48 (1291.43%)
Short Float %1.17%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)900%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 157.74 | ||
| P/S | 4.89 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.52
EYN/A
EPS(NY)0.01
Fwd EY0.63%
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0.29
BVpS-1.24
TBVpS-3.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -124.06% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-88.87%
ROA(5y)-67.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.24 | ||
| Quick Ratio | 0.24 | ||
| Altman-Z | -12.15 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.77%
EPS Next Y27.27%
EPS Next 2Y-583.06%
EPS Next 3Y-25.99%
EPS Next 5Y154.72%
Revenue 1Y (TTM)10183.69%
Revenue growth 3Y-46.59%
Revenue growth 5Y87.68%
Sales Q2Q%N/A
Revenue Next Year0%
Revenue Next 2Y-64.17%
Revenue Next 3Y4.7%
Revenue Next 5Y31.98%
EBIT growth 1Y-13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.78%
OCF growth 3YN/A
OCF growth 5YN/A